Fig. 6.

BR/OV-2 TNBC PDX tumors are sensitive to Hsp90 inhibition. (A) The BR/OV-1/2 classifier was used to calculate a BR/OV-1/2 Subgroup Score for each of 88 BRCA PDX models. The models with the highest (BR/OV-2-like, red) and lowest (BR/OV-1-like, blue) Scores were selected for functional testing. (B/C) Tumors were implanted s.c. into mice. Tumor dimensions were serially measured using calipers. Tumor-bearing mice were randomized to treatment as indicated. Tumor volumes were analyzed by linear mixed modeling to compare treatment groups. Arrow in (C) denotes time point when mice were switched from twice-weekly to once-weekly treatment. (D/E) Tumors (n=4/group) were analyzed by Ki67 IHC or TUNEL. Data are shown as mean + SE, and were analyzed by multiple comparison-adjusted Bonferroni post-hoc test. (F) Tumor lysates were analyzed by immunoblot. FL-Full-Length. CL-Cleaved. EL-Extra-Long. L-Long. S-Short. (G) RNA-seq profiles from TNBC and OVCA tumors from TCGA were used to calculate a BR/OV-1/2 Subgroup Score for each tumor.